<p>Capricor Therapeutics（納斯達克代碼：CAPR - 獲取免費報告）於週四發佈了季度財報。這家生物技術公司報告的每股收益為（$0.62），低於市場共識預期的（$0.51），差距為（$0.11），FiscalAI 報道。</p>
<p>獲取 <strong>Capricor Therapeutics</strong> 的提醒：</p>
<h2>Capricor Therapeutics 股票下跌 0.4%</h2>
<ul>
<li>Capricor Therapeutics 股價上漲超過 100%，可能會進一步上漲</li>
</ul>
<p>週四中午交易時，CAPR 股票下跌 $0.15，達到 $33.42。該公司共交易了 1,224,128 股股票，而其平均交易量為 1,328,225 股。該公司的市值為 18.5 億美元，市盈率為 -18.57，貝塔值為 0.37。Capricor Therapeutics 的 12 個月最低價為 $4.30，最高價為 $40.37。該公司的 50 日移動平均價格為 $25.57，200 日移動平均價格為 $16.24。</p>
<h2>機構投資者對 Capricor Therapeutics 的看法</h2>
<p>幾家機構投資者和對沖基金最近對該公司的持倉進行了調整。加拿大皇家銀行在第四季度增持了 Capricor Therapeutics 的股份，增幅為 12.4%。加拿大皇家銀行目前擁有 5,040 股該生物技術公司的股票，價值 146,000 美元，此前在上個季度增持了 557 股。Orion Portfolio Solutions LLC 在第四季度購買了 Capricor Therapeutics 的新股份，價值約 239,000 美元。紐約州共同退休基金在第四季度增持了 Capricor Therapeutics 的股份，增幅為 124.1%。紐約州共同退休基金目前擁有 13,000 股該生物技術公司的股票，價值 375,000 美元，此前在上個季度增持了 7,200 股。Voleon Capital Management LP 在第三季度購買了 Capricor Therapeutics 的新股份，價值約 311,000 美元。最後，Moneta Group Investment Advisors LLC 在第三季度增持了 Capricor Therapeutics 的股份，增幅為 25.5%。Moneta Group Investment Advisors LLC 目前擁有 34,454 股該生物技術公司的股票，價值 248,000 美元，此前在上個季度增持了 7,000 股。機構投資者持有該公司 21.68% 的股份。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位股票分析師最近對 CAPR 股票發表了看法。Oppenheimer 將 Capricor Therapeutics 的目標價格從 $22.00 上調至 $54.00，並在 12 月 8 日的研究報告中給予該公司 “跑贏大盤” 的評級。Alliance Global Partners 在 12 月 3 日的研究報告中重申了對 Capricor Therapeutics 的 “買入” 評級。Maxim Group 在 12 月 4 日的研究報告中將 Capricor Therapeutics 的目標價格從 $25.00 上調至 $50.00，並給予該股票 “買入” 評級。Wall Street Zen 在 1 月 11 日的研究報告中將 Capricor Therapeutics 的評級從 “持有” 下調至 “賣出”。最後，瑞銀集團在 12 月 15 日的研究報告中設定了 Capricor Therapeutics 的目標價格為 $50.00。九位投資分析師對該股票給予了 “買入” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價格為 $40.82。</p>
<p><strong>閲讀我們對 Capricor Therapeutics 的最新分析</strong></p>
<h2>更多 Capricor Therapeutics 新聞</h2>
<p>以下是本週影響 Capricor Therapeutics 的主要新聞：</p>
<ul>
<li>積極情緒：FDA 恢復對 deramiocel 的審查並解除之前的暫停——該機構已重新開啓對 deramiocel 的 BLA 審查，這是一個重要的監管催化劑，增加了最終批准的可能性，並設定了正式的決策時間表。閲讀更多。</li>
<li>積極情緒：最新的 3 期 HOPE-3 數據顯示臨牀上有意義的功能益處——在 2026 年 MDA 會議上展示的額外分析增強了該療法在 DMD 中的療效故事，支持了批准的可能性和長期商業潛力。閲讀更多。</li>
<li>積極情緒：臨牀信號擴展到心臟終點——HOPE-3 的報道顯示關鍵心臟功能指標的改善，這是 DMD 患者的重要商業和安全考慮。閲讀更多。</li>
<li>積極情緒：分析師支持——HC Wainwright 重申了 “買入” 評級，這可以幫助情緒和零售/機構的興趣，隨着監管透明度的提高。閲讀更多。</li>
<li>中性情緒：即將發佈的財報和短期催化劑——Capricor 預計很快將發佈季度業績；財報和管理層評論可能會影響短期走勢。閲讀更多。</li>
<li>中性情緒：空頭頭寸數據混亂——最近的報告顯示異常/零空頭頭寸數據，且幾乎沒有覆蓋天數；對擠壓動態或賣壓的影響不明確。（數據摘要）</li>
<li>消極情緒：監管風險依然存在——FDA 之前發出了完整回應信；審查的恢復並不保證批准，且該機構之前的異議強調了執行風險和二元監管結果。閲讀更多。</li>
</ul>
<h2>關於 Capricor Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>Capricor Therapeutics, Inc 是一家臨牀階段的生物技術公司，專注於開發用於心血管和罕見疾病的細胞和外泌體基礎的治療方案。公司總部位於加利福尼亞州比佛利山莊，利用專有的心臟球體衍生細胞（CDC）技術來解決以炎症、纖維化和組織退化為特徵的疾病。自成立以來，Capricor 已通過多項臨牀試驗推進其主要候選藥物，並建立了涵蓋細胞治療和細胞外囊泡（外泌體）平台的產品管線。</p>
<p>該公司的主要產品候選藥物 CAP-1002 由異體 CDC 組成，正在評估用於杜氏肌營養不良症（DMD）和與 COVID-19 相關的心臟損傷等適應症。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Capricor Therapeutics</li>
<li>用這四個簡單步驟讓你的銀行賬户 “防聯儲”</li>
<li>華爾街害怕的黃金圖表……</li>
<li>免費：可能改變你生活的加密峯會</li>
<li>歷史上最大的首次公開募股即將到來</li>
<li>在 2026 年 5 月 15 日之前購買這隻黃金股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Capricor Therapeutics 嗎？</h2>
<p>在考慮 Capricor Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Capricor Therapeutics 並不在名單上。</p>
<p>雖然 Capricor Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

2 倍做多納斯達克生物技術 ETF - ProShares

動態生物技術與基因組 ETF - Invesco

醫療業 ETF - SPDR

<p>Capricor Therapeutics（納斯達克代碼：CAPR）報告的季度每股收益為（$0.62），低於預期$0.11。股價下跌 0.4%，至$33.42，市值為 18.5 億美元。分析師的評級不一，普遍目標價為$40.82。機構投資者持有 21.68% 的股份。近期的積極進展包括 FDA 恢復對 deramiocel 的審查以及有希望的三期數據。然而，在之前收到 FDA 的完整回覆信後，監管風險依然存在</p>

<p>Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.11), FiscalAI reports.</p>
<div class="lb-trans"><p>Capricor Therapeutics（納斯達克代碼：CAPR - 獲取免費報告）於週四發佈了季度財報。這家生物技術公司報告的每股收益為（$0.62），低於市場共識預期的（$0.51），差距為（$0.11），FiscalAI 報道。</p>
</div><p>Get <strong>Capricor Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Capricor Therapeutics</strong> 的提醒：</p>
</div><h2>Capricor Therapeutics Stock Down 0.4%</h2>
<div class="lb-trans"><h2>Capricor Therapeutics 股票下跌 0.4%</h2>
</div><ul>
<li>Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>Capricor Therapeutics 股價上漲超過 100%，可能會進一步上漲</li>
</ul>
</div><p>Shares of CAPR stock traded down $0.15 during mid-day trading on Thursday, reaching $33.42. 1,224,128 shares of the company's stock traded hands, compared to its average volume of 1,328,225. The company has a market cap of $1.85 billion, a P/E ratio of -18.57 and a beta of 0.37. Capricor Therapeutics has a 12 month low of $4.30 and a 12 month high of $40.37. The company's 50-day moving average price is $25.57 and its 200-day moving average price is $16.24.</p>
<div class="lb-trans"><p>週四中午交易時，CAPR 股票下跌 $0.15，達到 $33.42。該公司共交易了 1,224,128 股股票，而其平均交易量為 1,328,225 股。該公司的市值為 18.5 億美元，市盈率為 -18.57，貝塔值為 0.37。Capricor Therapeutics 的 12 個月最低價為 $4.30，最高價為 $40.37。該公司的 50 日移動平均價格為 $25.57，200 日移動平均價格為 $16.24。</p>
</div><h2>Institutional Investors Weigh In On Capricor Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Capricor Therapeutics 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the company. Royal Bank of Canada increased its holdings in Capricor Therapeutics by 12.4% in the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company's stock valued at $146,000 after acquiring an additional 557 shares during the last quarter. Orion Porfolio Solutions LLC bought a new position in shares of Capricor Therapeutics during the 4th quarter valued at about $239,000. New York State Common Retirement Fund grew its position in shares of Capricor Therapeutics by 124.1% during the fourth quarter. New York State Common Retirement Fund now owns 13,000 shares of the biotechnology company's stock valued at $375,000 after purchasing an additional 7,200 shares in the last quarter. Voleon Capital Management LP purchased a new position in shares of Capricor Therapeutics during the third quarter valued at about $311,000. Finally, Moneta Group Investment Advisors LLC increased its holdings in shares of Capricor Therapeutics by 25.5% in the third quarter. Moneta Group Investment Advisors LLC now owns 34,454 shares of the biotechnology company's stock worth $248,000 after purchasing an additional 7,000 shares during the last quarter. Institutional investors own 21.68% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近對該公司的持倉進行了調整。加拿大皇家銀行在第四季度增持了 Capricor Therapeutics 的股份，增幅為 12.4%。加拿大皇家銀行目前擁有 5,040 股該生物技術公司的股票，價值 146,000 美元，此前在上個季度增持了 557 股。Orion Portfolio Solutions LLC 在第四季度購買了 Capricor Therapeutics 的新股份，價值約 239,000 美元。紐約州共同退休基金在第四季度增持了 Capricor Therapeutics 的股份，增幅為 124.1%。紐約州共同退休基金目前擁有 13,000 股該生物技術公司的股票，價值 375,000 美元，此前在上個季度增持了 7,200 股。Voleon Capital Management LP 在第三季度購買了 Capricor Therapeutics 的新股份，價值約 311,000 美元。最後，Moneta Group Investment Advisors LLC 在第三季度增持了 Capricor Therapeutics 的股份，增幅為 25.5%。Moneta Group Investment Advisors LLC 目前擁有 34,454 股該生物技術公司的股票，價值 248,000 美元，此前在上個季度增持了 7,000 股。機構投資者持有該公司 21.68% 的股份。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several equities analysts recently weighed in on CAPR shares. Oppenheimer increased their price target on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, December 8th. Alliance Global Partners reiterated a &#34;buy&#34; rating on shares of Capricor Therapeutics in a research note on Wednesday, December 3rd. Maxim Group increased their target price on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, December 4th. Wall Street Zen lowered Capricor Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Sunday, January 11th. Finally, UBS Group set a $50.00 price objective on shares of Capricor Therapeutics in a research report on Monday, December 15th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $40.82.</p>
<div class="lb-trans"><p>幾位股票分析師最近對 CAPR 股票發表了看法。Oppenheimer 將 Capricor Therapeutics 的目標價格從 $22.00 上調至 $54.00，並在 12 月 8 日的研究報告中給予該公司 “跑贏大盤” 的評級。Alliance Global Partners 在 12 月 3 日的研究報告中重申了對 Capricor Therapeutics 的 “買入” 評級。Maxim Group 在 12 月 4 日的研究報告中將 Capricor Therapeutics 的目標價格從 $25.00 上調至 $50.00，並給予該股票 “買入” 評級。Wall Street Zen 在 1 月 11 日的研究報告中將 Capricor Therapeutics 的評級從 “持有” 下調至 “賣出”。最後，瑞銀集團在 12 月 15 日的研究報告中設定了 Capricor Therapeutics 的目標價格為 $50.00。九位投資分析師對該股票給予了 “買入” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價格為 $40.82。</p>
</div><p><strong>Read Our Latest Analysis on Capricor Therapeutics</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Capricor Therapeutics 的最新分析</strong></p>
</div><h2>More Capricor Therapeutics News</h2>
<div class="lb-trans"><h2>更多 Capricor Therapeutics 新聞</h2>
</div><p>Here are the key news stories impacting Capricor Therapeutics this week:</p>
<div class="lb-trans"><p>以下是本週影響 Capricor Therapeutics 的主要新聞：</p>
</div><ul>
<li>Positive Sentiment: FDA resumes review of deramiocel and lifts prior hold — the agency has reopened the BLA review for deramiocel, a major regulatory catalyst that increases the probability of eventual approval and sets a formal decision timeline. Read More.</li>
<li>Positive Sentiment: Late-breaking Phase 3 HOPE-3 data show clinically meaningful functional benefits — additional analyses presented at the 2026 MDA conference strengthen the therapy’s efficacy story in DMD, which supports both approval probability and long-term commercial potential. Read More.</li>
<li>Positive Sentiment: Clinical signals extend to cardiac endpoints — coverage and reporting of HOPE-3 show improvements in key heart-function measures, an important commercial and safety consideration for DMD patients. Read More.</li>
<li>Positive Sentiment: Analyst support — HC Wainwright reiterated a Buy, which can help sentiment and retail/institutional interest as regulatory clarity improves. Read More.</li>
<li>Neutral Sentiment: Upcoming earnings and near-term catalysts — Capricor is projected to post quarterly results soon; earnings and management commentary can influence the short-term move. Read More.</li>
<li>Neutral Sentiment: Short-interest data are muddled — recent reports show anomalous/zero short-interest figures and effectively no days-to-cover; unclear impact on squeeze dynamics or selling pressure. (Data summary)</li>
<li>Negative Sentiment: Regulatory risk remains — the FDA previously issued a Complete Response Letter; resumption of review does not guarantee approval and the agency’s prior objections underscore execution risk and binary regulatory outcomes. Read More.</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：FDA 恢復對 deramiocel 的審查並解除之前的暫停——該機構已重新開啓對 deramiocel 的 BLA 審查，這是一個重要的監管催化劑，增加了最終批准的可能性，並設定了正式的決策時間表。閲讀更多。</li>
<li>積極情緒：最新的 3 期 HOPE-3 數據顯示臨牀上有意義的功能益處——在 2026 年 MDA 會議上展示的額外分析增強了該療法在 DMD 中的療效故事，支持了批准的可能性和長期商業潛力。閲讀更多。</li>
<li>積極情緒：臨牀信號擴展到心臟終點——HOPE-3 的報道顯示關鍵心臟功能指標的改善，這是 DMD 患者的重要商業和安全考慮。閲讀更多。</li>
<li>積極情緒：分析師支持——HC Wainwright 重申了 “買入” 評級，這可以幫助情緒和零售/機構的興趣，隨着監管透明度的提高。閲讀更多。</li>
<li>中性情緒：即將發佈的財報和短期催化劑——Capricor 預計很快將發佈季度業績；財報和管理層評論可能會影響短期走勢。閲讀更多。</li>
<li>中性情緒：空頭頭寸數據混亂——最近的報告顯示異常/零空頭頭寸數據，且幾乎沒有覆蓋天數；對擠壓動態或賣壓的影響不明確。（數據摘要）</li>
<li>消極情緒：監管風險依然存在——FDA 之前發出了完整回應信；審查的恢復並不保證批准，且該機構之前的異議強調了執行風險和二元監管結果。閲讀更多。</li>
</ul>
</div><h2>About Capricor Therapeutics</h2>
<div class="lb-trans"><h2>關於 Capricor Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.</p>
<div class="lb-trans"><p>Capricor Therapeutics, Inc 是一家臨牀階段的生物技術公司，專注於開發用於心血管和罕見疾病的細胞和外泌體基礎的治療方案。公司總部位於加利福尼亞州比佛利山莊，利用專有的心臟球體衍生細胞（CDC）技術來解決以炎症、纖維化和組織退化為特徵的疾病。自成立以來，Capricor 已通過多項臨牀試驗推進其主要候選藥物，並建立了涵蓋細胞治療和細胞外囊泡（外泌體）平台的產品管線。</p>
</div><p>The company's leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.</p>
<div class="lb-trans"><p>該公司的主要產品候選藥物 CAP-1002 由異體 CDC 組成，正在評估用於杜氏肌營養不良症（DMD）和與 COVID-19 相關的心臟損傷等適應症。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>閲讀更多</h2>
</div><ul>
<li>Five stocks we like better than Capricor Therapeutics</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>Free: The Crypto Summit That Could Change Your Life</li>
<li>The largest IPO in history is coming</li>
<li>Buy this Gold Stock Before May 15th, 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Capricor Therapeutics</li>
<li>用這四個簡單步驟讓你的銀行賬户 “防聯儲”</li>
<li>華爾街害怕的黃金圖表……</li>
<li>免費：可能改變你生活的加密峯會</li>
<li>歷史上最大的首次公開募股即將到來</li>
<li>在 2026 年 5 月 15 日之前購買這隻黃金股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0FQUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CAPR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Capricor Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Capricor Therapeutics 嗎？</h2>
</div><p>Before you consider Capricor Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Capricor Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Capricor Therapeutics 並不在名單上。</p>
</div><p>While Capricor Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Capricor Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Capricor Therapeutics (NASDAQ:CAPR) Posts Earnings Results, Misses Expectations By $0.11 EPS

Market Beat

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

美國制藥 ETF - iShares

醫療業 ETF - Vanguard

標普生物技術 3 倍做多 - Direxion

Invesco Nasdaq Biotechnology ETF

標普生物技術 ETF - SPDR

基因改革 ETF - ARK

標普生物技術 3 倍做空 - Direxion

Capricor治療

納斯達克生物科技指數 ETF - iShares Nasdaq

Capricor 治療公司（納斯達克股票代碼：CAPR）發佈了財報，收益每股比預期低 0.11 美元